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Kodappully Siveen2, Mohamed A. Yassin5, Maria Monne6, Muthanna Samara7, Richard Cook1, 
Claudio Sorio3, Helmout Modjtahedi1 & Nader I. Al‑Dewik1,8,9*
Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor‑like family protein 
tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies 
reported the down‑regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). 
In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to 
treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry 
to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML 
patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 
CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. 
The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with 
monoclonal antibody (TPγ B9‑2) and RT‑qPCR, and BCR-ABL1 transcript by RT‑qPCR, respectively. 
PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time 
of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate 
restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. 
Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib 
compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of 
CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML 
patients.
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PE-CY7  A tandem fluorochrome consisting of R-phyco erythrin
BV  Brilliant violet
CBC  Complete blood count
CML  Chronic myeloid leukemia
CP  Chronic phase
EDTA  Ethylenediaminetetraacetic acid
ELN  European LeukemiaNet
F  Failed treatment
FACs  Fluorescence-activated cell sorting
FDA  Food and Drug Administration
FISH  Fluorescence in situ hybridization
FU  Follow up
H  Healthy individuals
HMC  Hamad Medical Corporation
HSCs  Hematopoietic stem cells
IM  Imatinib Mesylate
IgG  Immunoglobulin G
IS  International scale 
LSCs  Leukemic stem cells
L  Lymphocytes
L,M,N  Lymphocytes, monocytes, and neutrophils
M  Monocytes
mAb  Monoclonal antibody
MFI  Mean fluorescent intensity
MMR  Major molecular response
MOPH  Ministry of Public Health
mRNA  Messenger RNA
N  Neutrophils
ND  New diagnosis
PCR  Polymerase chain reaction
Ph+  Philadelphia chromosome
PBCs  Peripheral blood cells
PTPRG  Protein tyrosine phosphatase receptor gamma
PBS  Phosphate-buffered saline
RT-qPCR  Reverse transcription PCR
SSC  Side scatter
SD  Standard deviation
SPSS  Statistical Package for the Social Sciences
W  Shapiro–Wilk
TKIs  Tyrosine kinase inhibitors
WSRT  Wilcoxon Signed-Ranks Test
Chronic myeloid leukemia (CML) accounts for 15–20% of all hematological malignancies amongst  adults1. BCR/
ABL is the first oncoprotein discovered in patients with CML and the first target for therapeutic intervention 
with small molecule tyrosine kinase inhibitors (TKIs) based  drugs2. To date, five different BCR-ABL TKIs (i.e., 
Imatinib Mesylate (IM), Nilotinib, Dasatinib, Ponatinib, and Bosutinib) have been approved by the United States 
Food and Drug Administration (FDA) for the treatment of patients with  CML3. However, primary or secondary 
resistance to treatment with TKIs occur in some patients with CML, highlighting the need for better understand-
ing the mechanisms of resistance and identification of the predictive biomarkers for the response to  treatment4.
Protein Tyrosine Phosphatase Gamma (PTPRG) is a tumor suppressor and a member of a family of recep-
tors tyrosine  phosphatases5. It has the ability to remove a phosphate group from the phosphorylated amino acid 
tyrosine that is present on its substrate protein, thus balancing the ABL1 tyrosine kinase  activities6. PTPRG is 
located on the short arm (3p14.2) of chromosome 3 and consists of 30 exons. It has an extracellular domain, 
a transmembrane domain, a carbonic anhydrase-homologous amino terminus followed by a fibronectin III 
domain, and two intracellular PTPase catalytic domains of which the only one is  active7. PTPRG regulates 
hematopoietic differentiation processes and is expressed in human hematopoietic precursor cells, as well as in 
neutrophils and  monocytes8.
In 2010, Della Peruta et al. reported down-regulation PTPRG at both mRNA and protein levels in leukocytes 
of CML  patients9. The status of PTPRG has also been reported to be important in the response to treatment 
with TKIs in CML  patients10. In another study, our group identified a single Nucleotide Polymorphism (SNPs) 
(rs62620047) in PTPRG (Y92H) in patients who failed Imatinib Mesylate (IM)  treatment11. More recently, hyper-
methylation of PTPRG loci was reported to be a molecularly independent mechanism of resistance to treatment 
with TKI in CML  patients12.
Flow cytometry is a simple and robust technique employed in many laboratories for the diagnostic and 
research purposes. It can also be of potential value in the monitoring of CML patients and their response to 
therapeutic  intervention13–16. In a previous study, we described the production of a monoclonal antibody that 
recognizes the extracellular domain of PTPRG (TPγ B9-2) on CML cell lines and patients’ samples. This is a 
unique antibody with a potential capacity for monitoring the PTPRG expression in CML  patients17.
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In this study, using flow cytometry, we determined the expression levels of PTPRG amongst a sub-population 
of white blood cells in healthy individuals and CML patients at the time of diagnosis and following treatment 
with TKIs. We also compared the effect of TKIs on BCR-ABL1 and PTPRG transcripts via Reverse Transcriptase 
PCR (RT-qPCR).
Results
To our knowledge, mAb TPγ B9-2 is currently the only mAb for use in the detection of PTPRG protein by flow 
cytometry. Therefore, in this study, the changes in the expression level of PTPRG protein were determined in 
the WBCs of seven healthy individuals and 21 CML patients at the time of diagnosis and following treatment 
with BCR-ABL TKIs, using flow cytometry.
Characteristics of CML patients at the time of diagnosis, their responses to the treatment 
with TKIs and healthy control participants. Out of the 21 CML patients examined in this study, 18 
(86%) were diagnosed at chronic phase (CP) and 3 (14%) at accelerated phase (AP)18. The mean age of the 
21 CML patients was 38.21 years and those of seven healthy controls 35.2 years. Eleven patients were treated 
with Imatinib (400 mg) and of these only two patients had optimal responses. Optimal response has also been 
developed in one patient following treatment with 600 mg of Imatinib. Out of the remaining nine CML patients 
treated with Nilotinib (300 mg), seven patients had optimal responses and the remaining two patients failed 
responses (Table 1). Overall, out of 21 CML treated patients with TKIs, 11 patients had optimal responses (52%), 
and ten patients had failed treatment (48%), (Table 1). In addition, the results of Fisher’s Exact Test revealed 
that treatment with Nilotinib (300 mg) was more likely to lead to optimal response compared to treatment with 
Imatinib (400 mg) (Odds Ratio: 15.75, 95% CI 1.75–141.41, Z: 2.46, p < 0.05) (Table 2A).
Presentation of results. Figure 1 shows the sequence of results and analysis that were performed using 
two techniques at different time points (diagnosis and follow up) for different comparisons.
Expression of BCR-ABL1 and PTPRG mRNA in whole white blood cells using RT‑qPCR. The 
expression levels of BCR-ABL1 and PTPRG mRNA levels in CML patients at diagnosis and follow up were 
determined by RT-qPCR and the results are presented in Fig. 2. As the results of Cohn’s d coefficient analysis 
show, there was a “huge” and “large” effect size on BCR-ABL1 (Cohen’s d = 5.05) and PTPRG transcripts (Cohen’s 
d = 0.81) following treatment with TKIs. A significant difference was found in the mean levels of BCR-ABL1 
mRNA at diagnosis and at follow up (WSRT p ˂  0.001, Fig. 2a) and PTPRG mRNA at diagnosis and at follow up 
(WSRT p ˂  0.001, Fig. 2b). In contrast to BCR-ABL1 mRNA, which had significantly higher levels at diagnosis 
Table 1.  CML patient’s characteristics: gender, age, clinical phase, TKIs (BCR/ABL1 and PTPRG) at diagnosis 
stage and response to treatment. a CML04 AP with additional chromosomal t(9:22) (q34, q11.2); t(11; 14) 
(q23, q32) (30). b CML13 CP with Tuberculosis. c CML20 AP with double Ph + . d CML14 patient lost to record 
myeloid lineage events at time of relapsed.
Patients Gender
Age 
(years) Diagnosis BCR-ABL1(IS) (%) PTPRG (%) Treatment Final response
CML 01 M 61 CP 37 0.02 Imatinib (400 mg) Failed
CML 02 M 61 CP 100 0.03 Imatinib (400 mg) Optimal
CML 03 F 33 CP 100 0.02 Nilotinib (300 mg) Optimal
CML 04 M 46 APa 100 0.01 Nilotinib (300 mg) Optimal
CML 05 M 23 CP 100 0.01 Imatinib (400 mg) Failed
CML 06 M 48 CP 100 0.02 Imatinib (400 mg) Optimal
CML 07 M 43 CP 100 0.02 Imatinib (400 mg) Failed
CML 08 M 36 CP 100 0.01 Imatinib (400 mg) Failed
CML 09 M 48 CP 100 0.02 Imatinib (400 mg) Failed
CML 10 M 45 CP 100 0.02 Imatinib (400 mg) Failed
CML 11 M 26 CP 100 0.01 Imatinib (400 mg) Failed
CML 12 F 28 CP 100 0.01 Nilotinib (300 mg) Optimal
CML 13 M 40 CPb 100 0.01 Imatinib (600 mg) Optimal
CML  14d M 45 CP 100 0.01 Nilotinib (300 mg) Failed
CML 15 M 26 CP 100 0.01 Imatinib (400 mg) Failed
CML 16 M 40 CP 100 0.01 Imatinib (400 mg) Failed
CML 17 M 33 CP 89 0.02 Nilotinib (300 mg) Optimal
CML 18 M 34 CP 100 0.02 Nilotinib (300 mg) Optimal
CML 19 M 32 AP 100 0.01 Nilotinib (300 mg) Optimal
CML  20d M 65 APc 100 0.01 Nilotinib (300 mg) Failed
CML 21 M 40 CP 100 0.01 Nilotinib (300 mg) Optimal
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compared to follow up, PTPRG mRNA expression levels were found to be significantly lower at diagnosis com-
pared to follow up. There was also a moderate negative correlation between BCR-ABL1 at diagnosis and PTPRG 
at follow up (rs (21) = − 0.422, p = 0.028).
Moreover, the PTPRG transcript was also assessed to compare between optimal and failed CML groups. The 
results showed that the optimal response group had significantly higher PTPRG expression during follow up 
(WSRT p ˂  0.0005) compared to diagnosis time-point, while no significant difference was found amongst the 
failed group at diagnosis and during follow up (WSRT p = 0.312, Fig. 2c).
PTPRG expression levels on white blood sub‑populations (WBCs) of Healthy individuals and 
CML patients at diagnosis using flow cytometry. Next, the expression levels of PTPRG protein were 
determined in the WBCs sub-populations of healthy and CML patients using flow cytometry and the results are 
presented in Figs. 3 and 4. A significant difference was found in the expression levels of PTPRG between different 
WBC sub-population (neutrophils, monocytes, and lymphocytes) [F (3, 5) = 19.15, p ˂  0.0001]. PTPRG protein 
expression levels were found to be higher on neutrophils and monocytes when compared to lymphocytes in both 
healthy individuals (Fig. 3a,b) and CML patients at diagnosis (Fig. 3c).
When comparing healthy individuals against CML patients, PTPRG protein expression levels were signifi-
cantly higher on neutrophils (U = 30, p < 0.002) and monocytes (U = 24, p < 0.007) amongst healthy individuals 
in comparison to CML patients at diagnosis (Fig. 3d). A significant difference was also found in the expression 
level of PTPRG on neutrophils between the healthy, optimal and failed groups (H = 14.94, df = 3, p = 0.001). The 
optimal response group had higher expression PTPRG in their neutrophils compared to the healthy group (U = 3, 
p = 0.004), and the failed groups had higher expression of PTPRG than the healthy group (U = 7, p = 0.004).
Expression levels of PTPRG protein on neutrophils and monocytes in optimal and failed 
groups at follow up determined by flow cytometry. The PTPRG expression level on WBCs was 
also re-assessed during the follow up for both optimal and failed CML groups. There was a significant differ-
ence between the expression of PTPRG on the neutrophils (χ2 (2, 11) = 13.82, p = 0.001) and monocytes (χ2 (2, 
Table 2.  (A) Contingency table of TKIs therapy with outcome response. *CML patients with IM 600 mg 
excluded from fisher exact estimation. (B) Test Statistics of effect of Nilotinib and Imatinib Mesylate on 
neutrophils.
(A) TKI therapy Optimal response Failure response Total
Imatinib Mesylate (400 mg) 2 9 11
Nilotinib (300 mg) 7 2 9
Total 9 11 20
(B) Time points
Nilotinib (300 mg) Imatinib Mesylate (400 mg)
Difference in mean rank P value Difference in mean rank P value
Diagnosis-1st follow up − 1.25 p = 0.03 − 0.83 p = 0.69
Diagnosis-2nd follow up − 2.38 p ˂  0.001 − 2.083 p ˂  0.001
Diagnosis-3rd follow up − 2.38 p ˂  0.001 − 2.75 p ˂  0.001
1st follow up–2nd follow up − 1.13 p = 0.49 − 1.25 p = 1.06
1st follow up–3rd follow up − 1.13 p = 0.488 − 1.91 p ˂  0.002
2nd follow up–3rd follow up 0.00 p = 1.0 − 0.667 p = 1.0
RT-qPCR
CML only
• BCR-ABL and PTPRG expression to compare between diagnosis and follow up




• PTPRG expression on white blood cells (WBCs): within and between all groups (H, 
CML, O, F). 
• PTPRG on LSC and HSC for CML only 
Flow cytometry
Follow up
• PTPRG expression on WBCs: within and between response groups (O & F). 
• PTPRG expression on WBCs (neutrophils only): The effect of Nilonib and Imanib 
treatments for CML paents 
Figure 1.  Presentation of results.
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11) = 10.09, p = 0.006) during the follow-up time points in the optimal response group. For the neutrophils, there 
were significant differences between 1st follow up (median: 3.68) and 2nd follow up (median: 4.8, Z = − 2.93, 
p ˂  0.001) and 1st follow up and 3rd follow up (median: 4.9) (Z = − 2.67, p ˂  0.001), but no significant differences 
between the 2nd and 3rd follow up (Z = − 0.89, p = 0.37, Fig. 5a). However, for the monocytes there were only 
significant differences in its expression levels between 1st follow up (median: 3.5) and 3rd follow up (median: 4.5, 
Z = − 2.05, p = 0.004, Fig. 5). There were no significant differences between the follow up time-points in relation 
to the expression of PTPRG on the lymphocytes in the optimal response group (χ2 (2, 11) = 2, p = 0.6).
In the failed response group, there were significant differences in the PTPRG expression levels between 1st 
follow up (median: 3.1) and 2nd follow up (median: 4.0) (Z = − 2.8, p ˂  0.005) and 1st and 3rd follow up (median: 
4.5, Z = − 2.6, p = 0.009), but no significant difference between 2nd and 3rd follow up (Z = − 1.33, p = 0.19, Fig. 5b). 
For the monocytes, there were significant differences between only the 1st follow up (median: 3.8) and 3rd follow 
up (median: 4.6), (Z = − 2.7, p = 0.027, Fig. 5). In contrast, there were no significant differences in the expression 
levels of PTPRG protein between the follow up time-points in the failed response group (χ2 (2, 10) = 2, p = 0.8).
When PTPRG expression was compared on neutrophils of optimal and failed group, there was no significant 
difference in the 1st follow up (U = 39, p = 0.26). On the other hand, there were significant differences between 
the two response groups at the 2nd follow up (U = 25.5, p = 0.036) and the 3rd follow up (U = 28.0, p = 0.05) 
(Fig. 5c). No significant differences in the monocytes of the optimal and failed groups were found between 
the follow up time points (1st follow up (U = 46.0, p = 0.53), 2nd follow up (U = 49.5, p = 0.7) and 3rd follow up 
(U = 48.0, p = 0.62)) (Fig. 5f).
In CML patients, the impact of treatment (Nilotinib vs. Imatinib) on neutrophils’ PTPRG expression sig-
nificantly differed over time (Nilotinib: χ2 (3, 8) = 18.45, p = 0.001; Imatinib: (χ2 (3, 12) = 32.9, p = 0.001). There 
Figure 2.  mRNA levels of BCR-ABL1 and PTPRG in CML patients at diagnosis and follow up. (a) BCR-ABL1 
transcript levels at diagnosis and follow up (mean of post-test ranks = 10 and mean of pre-test ranks = 94.24, 
Z = − 4.018, p ˂  0.001). (b) PTPRG transcript levels at diagnosis and follow up (mean of post-test ranks = 2.53 and 
mean of pre-test ranks = 0.3, Z = − 3.50, p ˂  0.001) (c) mRNA transcripts level of PTPRG in the optimal response 
and failed treatment groups. The mRNA level of PTPRG in the optimal response group was significantly higher 
when compared with diagnosis, while this significance was lost in the CML group. The Y-axis represents number 
of PTPRG/ABL1 of mRNA copies, while the X-axis represented timelines at diagnosis and mean of follow up. P 
values were derived from the WSRT test.
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was a significant treatment effect between diagnosis and 1st follow up (only for Nilotinib treatment) (U = 22, 
p = 0.047), between diagnosis and 2nd follow up (both treatments), and between diagnosis and 3rd follow up 
(both treatments). On the other hand, only Imatinib treatment was significantly more effective at the 3rd follow 
up compared to the 1st follow up (Table 2B).
Figure 3.  PTPRG protein expressions on sub-population of white blood cells of healthy individuals (H) 
and CML patients (ND). (a) Level of PTPRG expression on sub-population of white blood cells of (H). 
(Y-axis) refers to count numbers of peripheral blood cells recorded in each sub-population at flow cytometry 
acquisition. The expression of PTPRG was reported in Mean Fluorescent Intensity (MFI). (b) The mean of 
PTPRG expression (H) on both neutrophils (mean = 3.0), monocytes (mean = 2.8) was significantly higher 
when compared with lymphocytes (mean = 0.89). (c) The median of PTPRG expression (ND) on monocytes 
(median = 1.7); neutrophils (median = 1.5) was significantly higher when compared with lymphocytes 
(median = 1.14). (d) PTPRG expression on neutrophils and monocytes was significantly lower in CML (ND) 
patients in comparison with healthy individuals (H).
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PTPRG expression on myeloid progenitors within the optimal and failed groups. After analysis 
of mature population (WBCs), we studied PTPRG expression in two subpopulations of progenitors’ cells, leuke-
mic stem cell (LSCs) and hematopoietic stem cells (HSCs). The results show that there was no significant differ-
ence in PTPRG expression at the time of diagnosis (U = 31, p = 0.183), although the mean of PTPRG expression 
level on (LSC) (medium Glass’ Delta effect size: 0.52) was higher than HSC (small Glass’ Delta effect size: 0.17) 
(Table 3). Furthermore, the mean rank of PTPRG expression on LSC at the time of diagnosis in the failed group 
was significantly higher than the optimal group (U = 12, p < 0.004).
Discussion
In this study, for the first time we investigated the changes in the PTPRG protein level in CML patients at the 
State of Qatar determined by flow cytometry using a unique monoclonal antibody against the external domain 
of PRPRG. We confirmed that restoration levels of PTPRG were significantly greater during the follow-up period 
following treatment with BCR-ABL1 TKIs compared to the time of diagnosis (Fig. 4b). Moreover, stratification of 
CML patients’ response into optimal and failed treatment groups showed that the expression level of PTPRG to 
be significantly higher in the optimal response group when compared to the failed group, utilizing both q-PCR 
and flow cytometry techniques. Our results also confirmed our earlier findings using RQ PCR, in which 33 CML 
patients had been studied and the mRNA level of PTPRG was found to be significantly high in patient achieving 
Major Molecular Response (MMR), while this was not the case in non-responsive  cases17.
There is currently no clear associations between the expression of a biomarker at mRNA level and its transla-
tion at protein level and the link between the two parameters ranged from 40% up to 90%18–20. On the contrary, 
other publications reported a low correlation between levels of mRNA and protein expression due to many factors 
including steady state, degradation, proteomics, and transcriptomics  factors21–23. In the current study, we inves-
tigated the expression levels of PTPRG at both the mRNA and protein levels in parallel. While we did not find 
any significant differences in the expression of PTPRG at the mRNA level in the failed group (WSRT p = 0.312) 
(Fig. 2c), there were significant differences in the PTPRG protein expression level on neutrophils population 
in CML of the optimally treated group (Fig. 5c). Our results showed the importance of studying the expression 
levels of various biomarkers at both mRNA and protein levels.
In this study, we found that the restoration of the PTPRG level to be significantly higher on the neutrophils 
population in the optimal response group, when compared to the failed group at two follow up points (2nd and 
3rd follow up) (Fig. 5c). On the other hand, there was not a significant difference in the expression of PTPRG on 
the monocytes population between the optimal and the failed groups at any follow up point (Fig. 5f). Our data 
also showed that the restoration of PTPRG expression on neutrophils was drug-dependent as the expression of 
PTPRG was restored earlier with Nilotinib when compared to Imatinib Mesylate. This observation might reflect 
the superior potency of Nilotinib as BCR-ABL1 TKI, which was reported to be 20–50 times more potent than 
Imatinib, and its ability to achieve complete superior response compared to Imatinib  Mesylate24.
In another study, Naoto and his colleagues developed a fluorescence in situ hybridization (FISH) technique 
named “Neutrophil-FISH” that has the ability to classify CML cohort to responder and non-responder to 
Imatinib  Mesylate25. In the current study, we reported the ability of mAB TPγ B9-2 to record changes in expres-
sion of PTPRG on neutrophils by flow cytometry technique and consequently classify the CML patients in the 
same manner.
The restoration of PTPRG expression reached the level recorded in healthy individuals and this may be 
explained by the recovery of healthy hematopoiesis in these subjects due to that TKIs having a large impact on 
the PTPRG gene (Cohen’s d = 0.81). On the other hand, there was still a significant difference between levels of 
PTPRG in healthy, optimally, and failed groups. This may be explained by overexpression of PTPRG to overcome 
the uncontrolled BCR-ABL1 kinase activity.
In relation to expression of PTPRG on myeloid lineage, our previous study have shown a low level of PTPRG 
expression in CML on myeloid lineage at the time of  diagnosis17. Interestingly, in this study, we found the mean 
PTPRG expression level to be higher in hematopoietic stem cells when compared to leukemic stem cells. The 
Glass’ Delta effect size equation showed a small effect size of level of PTPRG at HSCs, as compared to a medium 
effect size of the level of PTPRG on LSCs (Table 3). Additionally, the expression of PTPRG on LSCs was signifi-
cantly higher in the failed group when compared to the optimal response. The result was matched with the fact 
that leukemic stem cells have a unique cell surface profile, which is different from that of hematopoietic  cells26. 
Furthermore, LSCs had the ability to self-renewal27, and LSCs had a signatory high expression of a gene, which 
is independently associated with adverse outcomes of  treatment28 and could predict the prognosis of the  disease29. 
A recent study documented that BCR-ABL1 transcripts maybe not transcribed by LSC of CML  patients30.
Finally, primary resistance and acquired resistance to treatment with BCR-ABL1 TKIs can occur in some 
patients with  CML31–34. In Qatar, a significantly higher percentage of CML patients develop resistance to TKIs 
compared to the other parts of the  world12,35. This may be due to the fact that most studies in CML management 
were focused on one component (tyrosine kinases), while the other arm (tyrosine phosphatases) has not yet 
received equivalent attention.
In summary, in this study, we have shown that the expression of PTPRG, a tumor suppressor gene, is sup-
pressed in CML patients and this can be restored following treatment with TKIs to levels observed in healthy 
controls. We have also shown that restoration levels were greatest in optimal responders and occurred earlier 
with nilotinib compared with imatinib. Taken together, our results support that determination of PTPRG expres-
sion level by flow cytometry as a new biomarker of response to treatment with BCR-ABL1 TKIs is a useful tool 
for studying its role in tumor progression and predicting the response to therapeutic interventions and clinical 
management in patients with CML.
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Materials and methods
Patient recruitment, characteristics and sample collection. Participants. A total of 21 adult CML 
patients whom were regularly followed up and treated with Tyrosine Kinase Inhibitors (Imatinib and Nilotinib) 
in the National Center for Cancer Care & Research clinics were recruited into this study. Peripheral blood sam-
ples were collected in EDTA tubes, where 63 subsequent samples were collected according to the ELN treatment 
timepoints. Seven matched healthy individuals (H) with normal complete blood count (CBC) and who were 
negative for BCR-ABL1 translocation were included in this study.
Patients’ blood samples, procedure, and ethics. Informed consent was obtained from all participants. The study 
was approved by both the Ministry of Public Health (MOPH) and the Institutional Review Board (IRB) of 
Hamad Medical Corporation (HMC) (Qatar) (Project No. 11118/11) and Kingston University London’s ethical 
committee (UK). This study adhered to the World Medical Association’s Declaration of Helsinki (1964–2008) for 
ethical human, research including confidentiality, privacy, and data management.
Blood samples were collected from newly diagnosed patients (ND) at day zero and before starting any tyrosine 
kinase inhibitor (TKI) or Hydroxyurea treatment. For failed/relapsed patients’ (F), blood samples were collected 
at the time of failure. The CML patients’ response to treatment was assessed based on the hematologic, cytoge-
netic, and molecular responses according to the European LeukemiaNet (ELN; 2013). The absence of one of the 
following was considered as treatment failure: abnormal complete blood count and/or  Ph+ > 95% by 3 months, 
BCR-ABL1 > 10% and/or  Ph+ > 35% by 6 months, or BCR-ABL1 > 1% and/or  Ph+ > 0 by 12 months  treatment36. 
The Optimal response group (R) was defined as achieving hematological, molecular, and cytogenetic remission 
within the time points of ELN guidelines.
Determination of PTPRG and BCR-ABL1 transcripts by RT-qPCR. A RT-qPCR was carried out to measure the 
mean levels of mRNA of PTPRG and BCR-ABL1 at 3, 6 and 12 months. Plasmids carrying PTPRG full length 
were utilized to standardize the number of copies measured by PCR as previously  described9,17,35,37,38. IPSOGEN 
BCR-ABL1 Mbcr IS-MMR Kits CE kit (Cat No. 670823) was utilized to quantify BCR-ABL1 according to the 
international scale (IS). RT-qPCR and Flow cytometry measurements were done simultaneously.
Flow cytometry. Isolated white blood cells (2 ×  106) were diluted into 200 μl phosphate-buffered saline (PBS1×) 
and transferred to FACs tubes (two tubes for isotope and PTPRG expression). The FACs tubes were placed on 
ice, and 5  μl CD45 primary antibody (Becton Dickinson international company (BD)-PE-CY7 anti-Human 
mouse Catalog No. 557748), 5 μl of CD34 antibody (BD-BV421 mouse anti-Human Catalog No. 562577), and 
20 μl CD38 antibody (BD-APC labeled anti-Human Catalog No. 555462) were added and incubated in the dark 
for 20 min at 4 °C according to supplier’s recommendations. After washing, 20 μl of mouse IgG1-AF 488 anti-
body (BD-mouse IgG1-AF 488 (20 μg) Catalog No. 557782) and 1 μl of TPγ B9-2-AF488 antibody (1 μg) were 
added and incubated in the dark for 40 min then washed twice with cold PBS at 200 × g for 5 min at 4 °C. The 
samples were then analyzed by flow cytometry (BD LSR FORTESSA cell analyzer), where 500,000–1,000,000 
numbers of events were targeted at acquisition records.
Flow cytometry was performed on peripheral blood cells (PBCs) to characterize the expression of PTPRG 
on lymphocytes, monocytes, and neutrophils (LMN). The gating strategy of the flow cytometry experiment 
aimed at monitoring PTPRG expression in the major populations represented by neutrophils, monocytes and 
lymphocytes at diagnosis and during the follow up phase of TKIs treatment (Fig. 4a,b).
L,M,N were gated with CD45 and side-scattered light (SSC). Neutrophils were characterized by intermediate 
CD45 and high SSC. Monocytes have a slightly higher CD45 expression and intermediate SSC, while lymphocytes 
have the highest expression of CD45 and the lowest level of SSC. Additionally, we targeted the level of PTPRG 
on myeloid lineages via the CD34 antibody and their sub-populations  (CD38+/−).  CD34+/CD38− (Dim) targeted 
leukemic stem cells (LSCs), while  CD34+/CD38+ (bright) targeted hematopoietic stem cells (HSCs). The expres-
sion of PTPRG was reported in Mean Fluorescent Intensity (MFI) that represents the difference in expression 
between Target of Interest (TOI) and an isotype control.
Figure 4.  Gating strategies of flow cytometric analysis of PTPRG protein and its expression during the 
treatment plan. (a) Gating strategies of PTPRG expression on the sub-population of white blood cells. 
Neutrophils (red color) have an intermediate level of CD45 and high side-scattered light (SSC); Monocytes 
(blue color) have a slightly higher level of CD45 expression and intermediate SSC while lymphocytes (green 
color) have the highest level of expression of CD45 but the lowest level of SSC. Doublets discrimination 
and exclusion of dead cells using 7-AAD staining (red rectangle) allow an easier identification of positively 
stained populations. In comparison the lower population was the target of part of the leukemic stem cell. (b) 
Neutrophils and Monocytes showed a low level of PTPRG expression at the time of diagnosis. PTPRG restored 
its expression, at least in part of the sub-population of white blood cells followed by TKIs therapy. Of note, 
lymphocytes remained at a low level acting as an internal control. Follow up time points F1, F2 and F3 were 
3, 6, and 12 months of successful TKIs as per ELN timelines. The MFI values were obtained by calculating the 
ratio differences between the signals derived from the signal of mAB TPγ B9-2 and irrelevant mouse IgG1. (c) 
Gating strategy to identify leukemic CD34+CD38− stem cells. For myeloid progenitors and its sub-population, 
we targeted 15–20% upper and lower population of CD34 (red color) with CD38, with the upper population 
corresponding to the target of interest (hematopoietic stem cells). In comparison the lower population 
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Statistical analysis. All statistical tests were performed using SPSS v26. Changes in mRNA levels of (BCR-
ABL1 & PTPRG) over timeline were analyzed with the Wilcoxon matched pairs signed ranks test (WSRT). The 
effect size of TKIs was reported and assessed on both genes (BCR-ABL1 & PTPRG) via the Cohen’s d coefficient 
for which d = 0.2 was considered a ‘small’ effect size, 0.5 a ’medium’ effect size, 0.8 a ’large’ effect size and 2.0 
Figure 5.  PTPRG protein expressions upon stratification of CML patients’ response in white blood cells and its 
sub-population. PTPRG level on neutrophils at diagnosis showed a median of 1.50 with negative skewness. (a) 
The restoration level of PTPRG on neutrophils of the optimal response group was greater in follow up periods 
compared to diagnosis phase, median Follow-up 1 = 3.68; median Follow-up 2 = 4.8; median of Follow-up 
3 = 4.9. Histogram showed positive skewness for later follow up periods. (b) PTPRG expression on neutrophils 
of failed response increased significantly by the first follow up compared to the time of diagnosis; median of 
Follow-up 1 = 3.065; median of Follow-up 2 = 4.0; median of Follow-up 3 = 4.5. Histogram of 1st and 2nd follow-
ups showed a normal distribution (Shapiro–Wilk test, W), while the 3rd follow up showed negative skewness. 
(c) Hodges–Lehmann estimator between optimally and failed groups on neutrophils; 1st follow up: − 0.78, 
2nd follow up: − 1.35 and 3rd follow up: − 0.9. PTPRG level on monocytes at diagnosis showed a median of 
1.7 with positive skewness. (d) The restoration of PTPRG level on monocytes of optimal response was greater 
in follow up periods when compared to diagnosis phase, medianFollow-up 1 = 3.5; median Follow-up 2 = 4.5; 
median Follow-up 3 = 4.5. Histogram of 1st and 2nd follow-up periods showed negative skewness, while the 3rd 
follow-up showed positive skewness. (e) The restoration of PTPRG level on monocytes in the failed response 
group showed a similar scenario as the optimal response group with a median Follow-up 1 = 3.8; median 
Follow-up 2 = 4.9; median Follow-up 3 = 4.6. The histogram of follow up periods showed a normal distribution 
(Shapiro–Wilk test, W). (f) Hodges–Lehmann estimator between optimally and failed groups on monocytes 1st 
follow up: − 0.34, 2nd follow up: − 0.35 and 3rd follow up: − 0.35. *Referred p-value was statistically significant. 
O optimal response, F failed group, ND new diagnosis, F1 1st follow up, F2 2nd follow up, F3 3rd follow up.
Table 3.  The expression level of PTPRG in the sub-population of myeloid progenitor cells.
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a “huge” effect  size39,40. Additionally, a Spearman’s rank-order correlation was run to determine the relationship 
between the two genes.
The distribution of the data was tested for normality with the Shapiro–Wilk test (W), and Skewness and 
normally distributed data was tested by the One-way Analysis Of Variance (ANOVA) and Dunnett’s multiple 
comparison tests. Non-normally distributed data was tested by Friedman and Dunnett’s multiple comparison 
tests. On the other hand, the Mann Whitney test was performed to analyze the difference between normally and 
non-normally distributed data. Changes in expression of PTPRG in CML patients over timeline were analyzed 
with Friedman and Wilcoxon signed ranks (WSRT) tests and a pairwise comparison with Hodges–Lehmann 
estimator. Finally, Kruskal–Wallis, along with Mann Whitney tests, were employed to examine the changes of 
PTPRG among healthy (H), optimally (R), and failed (F) groups.
Consent for publication. Consent for publication was obtained through ethics approval and consent to 
participate.
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